PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.58%
Negative EBIT growth while TRVN is at 41.47%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-14.34%
Negative operating income growth while TRVN is at 41.47%. Joel Greenblatt would press for urgent turnaround measures.
-20.40%
Negative net income growth while TRVN stands at 42.62%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-19.61%
Negative EPS growth while TRVN is at 45.70%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-20.61%
Negative diluted EPS growth while TRVN is at 45.70%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.76%
Share reduction more than 1.5x TRVN's 5.65%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.74%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-26.42%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-91846.40%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-21838.35%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
2.60%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
-1109485.80%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20425.82%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
78.21%
3Y net income/share CAGR above 1.5x TRVN's 37.76%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
41985.76%
10Y equity/share CAGR above 1.5x TRVN's 1101.74%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
3459.24%
5Y equity/share CAGR above 1.5x TRVN's 1101.74%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
143.15%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-29.04%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
15.43%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
12.93%
SG&A growth well above TRVN's 11.29%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.